https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Sanofi
Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer

Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer

Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), which is one of the most commonly diagnosed skin cancers. Libtayo, which is a fully-human monoclonal antibody targeting the immune checkpoint receptor programmed cell death […]

Praluent bags EC approval to reduce risk of CV events in patients with ASCD

Regeneron Pharmaceuticals and Sanofi have secured approval for Praluent (alirocumab) for a new indication from the European Commission (EC), which is for the reduction of cardiovascular risk in adults with established atherosclerotic CV disease (ASCD) by reducing low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correct other risk factors. Atherosclerotic CV Disease is defined […]

Continue reading …
Ablynx wins Cablivi FDA approval for rare blood clotting disorder

Cablivi FDA approval : Belgian biopharma company Ablynx has bagged approval from the US Food and Drug Administration (FDA) for its anti-vWF nanobody Cablivi (caplacizumab-yhdp) injection in combination with plasma exchange and immunosuppressive therapy for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). According to the FDA, aTTP is a rare blood clotting disorder in […]

Continue reading …
Sanofi, Regeneron report Dupixent FDA approval for asthma

Dupixent FDA approval : Dupixent (dupilumab), an eczema drug the co-developed by Sanofi and Regeneron Pharmaceuticals, has been approved by the US Food and Drug Administration as an add-on maintenance therapy for two forms of asthma. Dupixent FDA Approval The new Dupixent FDA approval is for treating patients with moderate-to-severe asthma aged 12 years and older […]

Continue reading …
Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]

Continue reading …
AstraZeneca, Sanofi form R&D alliance for infant respiratory drug

AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals. While MedImmune is the global biotech arm of British-Swedish pharma giant, Sanofi Pasteur is the vaccines division of French […]

Continue reading …
Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]

Continue reading …